Florida Cannabis: 930K Patients, 0.89g/Day, and a $6.2B Recreational TAM

Florida's medical cannabis program is the most data-rich in the country. Every gram dispensed to every patient flows through mandatory state tracking. What the data shows is both a consumption baseline that validates the broader framework and a market that is structurally ready for recreational expansion the moment the policy barrier lifts.

Market Overview

Florida legalized medical cannabis under Amendment 2 in November 2016. The program operates under the Office of Medical Marijuana Use (OMMU) through a vertically integrated model — each licensed Medical Marijuana Treatment Center (MMTC) must cultivate, process, and dispense its own product. Adult-use cannabis remains illegal; the 2024 ballot initiative (Amendment 3) received 56% voter support but fell short of the 60% constitutional threshold.

Key metrics:

• 738 dispensaries statewide (Jan 2026, OMMU)
• ~930,000 active patients (Q4 2025)
• 297 metric tons consumed in 2025 (51 weeks of OMMU data)
• 0.89 g/day per-patient consumption (flower-equivalent)
• ~$1.8–2.0 billion estimated 2025 medical revenue
• ~21% estimated resident capture at current medical pricing
• 25 licensed MMTCs operating vertically integrated supply chains

The 0.89 g/Day Validation

Florida has something no other state can offer: consumption data derived from mandatory track-and-trace across 930,000 patients with real financial skin in the game. Survey self-report isn't involved. Ghost accounts aren't counted. Every gram dispensed to every registered patient appears in the weekly OMMU reports.

The result is 0.89 grams per day — the most defensible per-patient consumption figure in the country.

This figure lands directly inside the validated 0.5–0.7 g/day flower range and aligns with the 1.0 g/day flower-equivalent baseline when non-flower products are included on a THC-equivalent basis — consistent with consumption patterns measured across seven North American jurisdictions. Florida's medical program, with its mandatory patient registry and financial access barrier, selects for higher-frequency users. The 0.89 g/day floor is not suppressed by design constraints; it reflects what committed cannabis consumers actually use.

The Q2 elevation (0.93 g/day) reflects the 4/20 promotional effect — week 17 alone recorded 508M mg THC dispensed, demonstrating clear price elasticity. The Black Friday week (week 48) showed the year's peak: 494M mg THC and 156,726 oz flower in a single week, 19% above the weekly average.

Tax Structure and the $332 Barrier

Florida's medical program imposes annual costs that function as a participation filter:

• Physician recommendation: $150 per certification, required every 7 months → ~$257/year annualized
• State registry fee: $75/year
• Total annual overhead: ~$332

For a patient consuming 0.89 g/day at current pricing, the $332 overhead adds roughly 15% to annual cannabis costs — meaningful but manageable for regular consumers. For casual or infrequent users, it's prohibitive. The $332 barrier is why Florida's program captures approximately 21% of estimated total resident demand rather than the 95%+ a well-designed recreational market would achieve.

Medical programs by design serve the committed consumer. The 75% of Florida cannabis demand not flowing through licensed channels represents people for whom the friction exceeds the benefit — not people who don't want legal cannabis.

Total Addressable Market

Florida's adult population 21+ is approximately 16.5 million. Applying the empirically validated consumption baseline of 18% participation at 1.0 gram per day:

• 16.5 million adults 21+
• 2.97 million estimated regular consumers (18%)
• 1,083 metric tons annual demand (2.97M × 365g)

At $6/g pre-tax — consistent with current medical pricing after sustained compression and the expected recreational launch price — Florida's resident TAM is $6.5 billion. The medical market's 297 MT represents approximately 27% of this total, matching the expected capture profile of a high-friction medical-only program.

Recreational Market Forecast

At a 16.5% total tax burden (10% excise + 6.5% sales tax), Florida's recreational market projects as follows:

The 16.5% tax rate sits in the empirically validated range where legal markets achieve full or near-full capture:

At $6/g legal retail with 16.5% tax ($7/g out the door), legal cannabis is price-competitive with the black market in Florida. The 5% residual represents privacy-motivated non-participants, deep rural consumers beyond reasonable dispensary access, and social gifting — not price-driven illicit preference.

Revenue will compress below $6/g as recreational competition drives prices down, as it has in every mature legal market. The TAM in dollar terms will shrink as grams-sold grows. That's the mature market trajectory, not a failure condition.

The Enforcement Advantage

Florida has achieved something California and New York have not: zero unlicensed THC storefronts operating openly. The 25 vertically integrated MMTCs with 738 locations provide statewide coverage with a compliance footprint regulators can actually monitor. Seed-to-sale tracking is operational and battle-tested across 8+ years and 930K patients.

The vertical integration model drew criticism during Amendment 3 debates as anti-competitive. The enforcement record answers that critique directly: a concentrated, accountable supply chain is why Florida's black market is suppressed rather than dominant. California's fragmented structure — 150+ cultivators, 1,000+ retailers — is precisely why enforcement collapsed there.

Recreational expansion doesn't require dismantling this structure. It requires adding access layers on top of a functioning foundation. The 738 dispensaries are Day 1-ready for adult sales. The supply chain that moves 297 MT annually to 930K patients can scale to serve a 3M+ consumer base without rebuilding from scratch.

Home Cultivation

Florida currently prohibits home cultivation entirely — no plants permitted under any circumstances, medical or otherwise. In a recreational framework, some home grow allowance is the norm, but as documented across every market that permits it, the revenue impact is negligible. At $6/g retail with no setup cost, time investment, or expertise required, legal dispensaries are simply more economical for virtually all consumers. The 3–5% of users who grow in permissive markets do so for reasons — quality control, strain selection, self-sufficiency — that wouldn't convert to retail spending anyway. Florida's prohibition on home grow is not a meaningful driver of capture rate in either direction.

What the CHS Literature Missed

Florida's OMMU program generates the most reliable cannabis consumption data in the country — 319 weeks of mandatory dispensation records across a patient population that pays $332 annually for access. That data became the empirical basis for a behavioral falsification test of high CHS prevalence claims: if 17–33% of daily users develop CHS as some clinical estimates suggest, Florida's 930,000 registered patients should include 79,000–154,000 active sufferers. A syndrome at that scale produces observable market behavior — patients cycling out, consumption declining among long-tenure users, emergency department volume generating public health responses. None of that appears in 319 weeks of OMMU data. Consumption per patient has been stable to rising. The program that generates the most granular cannabis consumption dataset in North America has never issued a CHS advisory, and the data explains why.

The OMMU's patient education materials cover dosing, pregnancy, driving impairment, and youth access. CHS does not appear. That omission from a mandatory reporting infrastructure is not an oversight — it reflects what the dispensation record actually shows about how frequently committed daily consumers exit the market due to hyperemesis.

The Bottom Line

Florida's medical program is simultaneously the strongest argument for recreational legalization and the clearest demonstration of what a medical-only barrier costs. The 0.89 g/day consumption data is the most reliable per-patient figure in the country and validates the 1.0 g/day framework baseline. The 297 MT of annual patient consumption represents roughly 27% of estimated total demand — meaning approximately 786 MT flows through unlicensed channels every year, not because Floridians prefer the black market but because the $332 annual barrier prices out everyone except committed regular consumers.

Recreational legalization at 16.5% removes that barrier. The infrastructure exists. The supply chain is proven. The enforcement model works. The $6.2 billion TAM reflects what happens when 2.97 million consumers can access a market that 930,000 patients have already validated at $6/g pricing.

This analysis applies the Dan K Reports Cannabis Market Framework. For methodology, assumptions, and the complete state-by-state comparison, see the framework documentation.